Label each vial with the reconstitution date using permanent marker
Injectable NAD+ is the more established option and tends to deliver the strongest, most noticeable results
The recent Semaglutide Cardiovascular Outcomes Trial (SOUL) reported that once-daily oral semaglutide (maximal dose, 14 mg), in addition to standard care, significantly reduces the risk of MACE in individuals with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both, without an increase in the incidence of serious adverse events [6]
R., Graber, T
Wegovy has become a notable option in the realm of chronic weight management, particularly among individuals grappling with obesity
To further understand this, we conducted studies to assess how GLP-1 may affect inflammation, focusing on the role of the GLP-1Rs in the gut